Prognosis
Novartis Raises Mid-Term Growth Forecast After Restructuring
- Sales will likely rise 5% annually, up from 4% estimate
- CEO says Swiss drugmaker completed its transformation
This article is for subscribers only.
Novartis AG raised its mid-term sales growth forecast as the Swiss drugmaker focuses on its medicines with the highest profit potential.
Sales should increase 5% annually through 2027, the company said Tuesday. The core operating margin should be about 40% or more by then.